All Oncology News

The incorporation of immune checkpoint inhibitors has altered the treatment paradigm for endometrial cancer.

A survey of practicing oncologists in the United States revealed that clinicians have ethical concerns surrounding the use of AI in cancer care.

Daniel P. Petrylak, MD, discusses advancements in the treatment of patients with bladder cancer.

Health systems have put a stronger emphasis on making preventive care accessible, contributing to a reduction in colorectal cancer incidence and mortality.

Wenxin (Vincent) Xu, MD, discusses the evolving landscape of systemic therapy in RCC, sharing how he makes treatment decisions amid the changing treatment space.

Voruciclib plus venetoclax had antileukemic activity with acceptable safety in patients with relapsed or refractory acute myeloid leukemia.

Shivaani Kummar, MBBS, FACP, discusses the mechanism of action of the TP53-directed agent rezatapopt and efficacy data with this agent in solid tumors.

CTL019 CAR T-cell therapy plus time-limited ibrutinib resulted in high complete response rates in relapsed/refractory mantle cell lymphoma.

Dmitriy Zamarin, MD, PhD, highlights key changes and ongoing research across the endometrial, ovarian, and cervical cancer realms.

Brooke Worster, MD, MS, FACP, and chief medical officer at EO Care, details what oncologists should know about medical cannabis pending the expectant marijuana reclassification from a Schedule I to a Schedule III drug.

LSTA1 has received rare pediatric disease designation from the FDA for the treatment of patients with osteosarcoma.

UCSF researcher to lead multicenter precision medicine trial for juvenile myelomonocytic leukemia.

A deep dive into IL-15 targeted agents including N-803, those in the pipeline, and the fusion protein SAR445877 which Martin E. Gutierrez, MD, sheds light on.

Elias Jabbour, MD, expands on the significance of ponatinib’s approval in Philadelphia chromosome–positive acute lymphoblastic leukemia.

Adagrasib improved progression-free survival and objective response rates vs docetaxel in pretreated KRAS G12C–mutant non–small cell lung cancer.

Sunil Iyer, MD, expands on the potential role of imetelstat for select patients with lower-risk myelodysplastic syndrome.

China’s NMPA accepted a sBLA for enfortumab vedotin plus pembrolizumab for the first-line treatment of locally advanced or metastatic urothelial cancer.

Ibrutinib with or without rituximab was effective and tolerable in patients with previously untreated, low-risk mantle cell lymphoma.

Huntsman Cancer Institute at the University of Utah received $75 million from the Utah Legislature toward a cancer research and academic building.

China’s NMPA has accepted an sNDA for approval of savolitinib for treatment-naive locally advanced/metastatic NSCLC with MET exon 14 skipping alterations.

Experts discuss updated findings from key clinical trials in hepatocellular carcinoma presented during the 2024 Gastrointestinal Cancers Symposium.

The European Commission has approved neoadjuvant pembrolizumab plus chemotherapy, followed by adjuvant pembrolizumab, for high-risk, resectable NSCLC.

Incorporating the Breast Cancer Index test assay into practice affected clinicians’ decision to offer endocrine therapy in HR+ early-stage disease.

Experts delineate the latest developments and lingering questions in bladder and renal cancers, covering pivotal trials, emerging therapies, and optimal management approaches.

MK-1084 had an acceptable toxicity profile when administered as a monotherapy in patients with KRAS G12C–mutated previously treated solid malignancies.

Patients with myeloproliferative neoplasms in accelerated or blast phase experience improved survival outcomes after hematopoietic cell transplantation.

Jason Efstathiou, MD, discusses the status of bladder preservation therapy for muscle-invasive bladder cancer.

Florida Cancer Specialists & Research Institute has opened a new facility in Orange City, FL, to provide comprehensive cancer care.

TTFields plus supportive care improved time to intracranial progression in patients with brain metastases from non–small cell lung cancer.

Capivasertib plus fulvestrant has been approved in Japan for pretreated, PIK3CA-, AKT1-, or PTEN-altered, HR-positive, HER2-negative breast cancer.